Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Werewolf Therapeutics ( (HOWL) ) has shared an announcement.
On February 24, 2026, Werewolf Therapeutics announced it is exploring a full range of strategic alternatives to advance its immunotherapy platform and pipeline and to maximize stockholder value. The company has retained Piper Sandler & Co. as its exclusive financial adviser and said potential options under review include a sale, merger, asset sale, licensing or collaboration deals, or other strategic transactions.
Management emphasized that there is no defined timeline for this review and no assurance that it will result in any transaction or agreement that enhances shareholder value. Werewolf also stated it does not plan to provide interim updates on the process unless its board approves a specific course of action or further disclosure is deemed necessary, leaving investors to weigh uncertainty around the company’s future structure and independence.
The most recent analyst rating on (HOWL) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Werewolf Therapeutics stock, see the HOWL Stock Forecast page.
Spark’s Take on HOWL Stock
According to Spark, TipRanks’ AI Analyst, HOWL is a Neutral.
The score is held down primarily by weak financial performance (large ongoing losses and cash burn with funding/dilution risk) and bearish technicals (downtrend across major moving averages with negative MACD). Positive pipeline progress and FDA-related updates provide some offset, but loss-making status and lack of dividend support keep the valuation component weak.
To see Spark’s full report on HOWL stock, click here.
More about Werewolf Therapeutics
Werewolf Therapeutics, Inc. is a biopharmaceutical company focused on developing immune-stimulating therapies for cancer and other immune-mediated conditions. It leverages its proprietary PREDATOR platform to design conditionally activated INDUKINE and INDUCER molecules, including lead candidates WTX-124, WTX-330, WTX-1011 and WTX-2022 for solid tumors, prostate, ovarian and kidney cancers.
Average Trading Volume: 608,942
Technical Sentiment Signal: Sell
Current Market Cap: $31.98M
See more insights into HOWL stock on TipRanks’ Stock Analysis page.